Cohance Lifesciences: FY25 Revenue ₹2,610 Cr, CEO Named

Company identity and corporate address

Cohance Lifesciences Limited is the new identity of erstwhile Suven Pharmaceuticals Limited. The company’s listed disclosures and investor information continue to reflect the transition to the Cohance Lifesciences brand. The corporate address referenced is 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai, Maharashtra. The contact number provided is 022-61539999.

The company operates as a bio-pharmaceutical business with a focus on development and manufacturing for global customers. Its work spans New Chemical Entity (NCE) based intermediates and active pharmaceutical ingredients (API), along with specialty chemicals and formulated drugs. The company also describes its reach as spanning India, the United States, Europe, and international markets.

2025 consolidation of CDMO platform

In 2025, the group consolidated its CDMO capabilities under Cohance Lifesciences. This consolidation is positioned as a platform move, bringing contract development and manufacturing activities under one identity. The company’s stated scope includes contract research, development, and manufacturing across multiple pharma-related product categories.

The consolidation matters for customers and investors because CDMO businesses are typically evaluated on delivery reliability, margins, and breadth of capabilities. Cohance’s disclosures emphasise integration and supply reliability, including for specific high-value product areas. The company also notes its activity in NCE-based intermediates, APIs, specialty chemicals, and formulations, which are core service lines for global innovators and generic manufacturers.

Leadership update: Umang Vohra appointed Group CEO

Cohance Lifesciences announced the appointment of Umang Vohra as Group CEO, effective May 20, 2026. The outgoing leader, Mr. Sharma, is set to continue as an advisor for around nine months to support the transition. The transition structure suggests a phased handover, with continuity built in through the advisory period.

For shareholders, senior leadership changes can influence execution pace, capital allocation discipline, and integration of acquired assets. In this case, the company has highlighted M&A investments in FY25, so continuity at the top can be an important governance signal. The company’s communications around the appointment focus on timing, role, and transition support, without detailing strategic changes.

Board meeting scheduled for financial results

Cohance Lifesciences informed BSE that a meeting of the Board of Directors is scheduled on 12/02/2026. The agenda includes considering and approving the unaudited financial results, both standalone and consolidated, for the quarter and nine months ending December 31, 2025.

Such board meetings are standard for listed companies, but they become closely watched when there is a rebranding, platform consolidation, and M&A activity. Investors often track these dates for clarity on segment performance, margin trajectory, and cash flow movement. The stated scope here is limited to approval of unaudited results for the specified periods.

Operations focus: NCE platform and ADC-related supply

Cohance states that it supplies payloads and the starting materials for these payloads, fully integrated in India, with an emphasis on supply reliability. It also notes that it is engaged in two of the twelve ADCs that have received global approval. This reference links Cohance to a specialised part of the pharmaceutical value chain where reliability and regulatory readiness can be critical.

The company’s described operating footprint spans India, the United States, and Europe, along with international markets. Across these geographies, CDMO operators are generally assessed on compliance track record and ability to scale manufacturing. Cohance’s disclosures in the provided text focus on integration and product categories, without adding new capacity or capex figures.

Quarterly performance: revenue growth and margin expansion

Cohance reported revenue of ₹549.3 crore, up 13% year-on-year. Gross margins expanded to 73.0% from 68.4% in Q1FY25. The company also reported EBITDA of ₹131.4 crore, with an EBITDA margin of 23.9%.

These figures point to improved profitability on the reported base, driven by stronger gross margin and steady operating leverage as reflected in EBITDA margin. Gross margin expansion from 68.4% to 73.0% is a key operational metric for a CDMO and specialty manufacturing model, where product mix and process efficiency can shift profitability. The company also reported revenue of ₹841.2 crore, up 20% year-on-year, in another disclosed period within the provided text.

FY25 snapshot: combined platform revenue and cash flow

For FY25, revenue grew 9.1% year-on-year to ₹2,610.3 crore on a combined platform. The company generated free cash flow of ₹361 crore during the year. It closed FY25 with ₹290 crore in cash and bank balances.

The cash position is reported alongside M&A investments of ₹806 crore during the year. The combination of positive free cash flow and significant M&A outflow provides investors a clearer picture of how internal cash generation and investment activity interacted in FY25. The data presented does not detail the specific acquisitions, but it establishes the scale of deployment versus year-end liquidity.

Stock snapshot and investor context

The stock information in the provided text shows a price of 458.30, down 1.70 or 0.37%, at close (3:30:01 PM GMT+5:30). It also lists a current share price of ₹457.80 and references the timestamp “As on 01 Jul, 2026 | 15:59”. Separately, the text notes “No news available” in the displayed feed section, even as it lists the CEO appointment under “What’s in the News”.

For market participants, these snapshots provide context rather than a causal link to any single event. The price and percentage change indicate a modest down move on the referenced close. Investors typically triangulate such moves with scheduled result dates, leadership updates, and margin performance, but the provided content does not attribute price movement to any one factor.

Key facts table

Why the update matters for CDMO investors

The combination of a rebranding, consolidation of CDMO capabilities, and a formal CEO transition shapes how investors frame execution risk and governance continuity. Financially, the provided numbers highlight revenue growth and improved profitability metrics in the reported quarterly data, including higher gross margin and a 23.9% EBITDA margin. FY25 data adds context on internal cash generation and the scale of M&A investments.

The operational note on payload supply and involvement in two of the twelve globally approved ADCs adds a product and customer relevance angle. However, the provided content does not include contract values, customer names, or order book data, so the significance is best read as strategic positioning rather than quantified demand.

Conclusion

Cohance Lifesciences has positioned itself as a consolidated CDMO platform under a new corporate identity, while reporting FY25 revenue of ₹2,610.3 crore and positive free cash flow of ₹361 crore. The appointment of Umang Vohra as Group CEO from May 20, 2026, alongside a nine-month advisory transition for Mr. Sharma, provides a defined leadership handover structure. The next confirmed milestone in the provided information is the board meeting scheduled on 12/02/2026 to consider unaudited financial results for the quarter and nine months ended December 31, 2025.